Evidence map›Paper›PMID 35035673›Full record

ReviewAmerican journal of translational research2021

Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.

Panagiotis Sarantis, Eleftheria Dikoglou Tzanetatou, Evangelia Ioakeimidou, Christos Vallilas, Theodoros Androutsakos, Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Athanasios G Papavassiliou, Michalis V Karamouzis

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Long Non-Coding RNA SNHG3 Promotes the Progression of Cholangiocarcinoma by Regulating the miR-151a-3p/STAT5a Axis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024
    Article
  7. Article
  8. Review
  9. Genetic alterations ofOpen life sciences · 2023
    Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Panagiotis SarantisMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens 11527 Athens, Greece.
Eleftheria Dikoglou TzanetatouMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens 11527 Athens, Greece.
Evangelia IoakeimidouMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens 11527 Athens, Greece.
Christos VallilasMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens 11527 Athens, Greece.
Theodoros AndroutsakosPathophysiology Department, Medical School, National and Kapodistrian University of Athens 11527 Athens, Greece.
Christos DamaskosN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens 11527 Athens, Greece.
Nikolaos GarmpisN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens 11527 Athens, Greece.
Anna GarmpiFirst Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens 11527 Athens, Greece.
Athanasios G PapavassiliouMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens 11527 Athens, Greece.
Michalis V KaramouzisMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens 11527 Athens, Greece.
National and Kapodistrian University of Athens · GRLaiko General Hospital of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) represents 3% of all gastrointestinal cancers worldwide and is the second most common primary liver tumor after hepatocellular carcinoma. CCA is an aggressive tumor that involves the intrahepatic, perihilar and distal biliary tree, with a poor prognosis and an increasing incidence worldwide. Various genetic and epigenetic factors have been implicated in CCA development. Gene mutations involving apoptosis control and cell cycle evolution, histone modifications, methylation dysregulation and abnormal expression of non-coding RNA are the most important of these factors. Regarding treatment, surgical resection, cisplatin and gemcitabine have long been the most common treatment options, but 5-year survival (7-20%) is disappointing. For that reason, inhibitors and small molecules related to specific mutations and molecular pathways have been introduced. Among them, immunotherapy seems to be a promising treatment in CCA, with multiple regimens being under clinical trial studies. The combinatorial therapy of traditional CCA treatment with tyrosine kinase inhibitors and/or immunotherapy seem to be the future, depending on the molecular profile of each patient's tumor.

Indexed as

Cholangiocarcinomaepigeneticsgenetic mutationsimmunotherapyinhibitors

Identifiers

PMID35035673
PMCPMC8748131
OpenAlexW4206845323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.